A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) (NCT01292473), a randomized phase 3 study. The primary outcome is Change From Baseline in the Weekly Itch Severity Score at Week 12.

2. Clinical Question

The question is about comparative change over the study period, rather than whether a participant reached a particular symptom threshold. The registry also lists secondary questions about overall urticaria activity, hive counts and size, itch response timing, quality of life, and angioedema-free days. Those measures provide a wider view of symptoms and related outcomes, but they do not replace the designated primary endpoint.

The posted group summaries describe changes in each arm, while the comparison estimates quantify the difference between an omalizumab arm and placebo. The sponsor’s reported analysis uses an adjusted model, so its estimates need not match simple differences calculated from the arm means. The tables and plots display these results; the discussion below explains how to read them without treating the arm-level changes as direct evidence of a between-group effect.

3. Trial Design

This was a Phase III, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, parallel-group study. The registry describes it as global and lists Genentech, Inc. as sponsor. The record gives an enrollment of 323 and a completed status. The listed study period began in 2011-03, with primary completion in 2012-06.

Participants were assigned to placebo or one of three omalizumab dose groups. The listed regimens were subcutaneous placebo every 4 weeks, or omalizumab 75 mg, 150 mg, or 300 mg subcutaneously every 4 weeks. The brief description identifies the treatment as add-on therapy for patients who remained symptomatic despite standard-dosed H1 antihistamine treatment. The record describes a population aged 12-75 with refractory chronic idiopathic urticaria, also referred to as chronic spontaneous urticaria.

Randomization is intended to make treatment groups comparable on average, while double blinding is intended to limit differences in expectations or assessment that could influence results. These are general design purposes; the registry record does not report the specific randomization procedure, allocation concealment details, or how blinding was maintained. It also does not report the original sample-size justification, the target number for each arm, or whether interim analyses were planned.

The primary endpoint is reported for the modified intent-to-treat population, defined in the record as all randomized patients who received at least one dose of study drug. The arm-level endpoint summaries show different analysis counts from the overall enrollment figure. These refer to the posted analysis population, and should not be read as a change to the enrollment figure. The detailed disposition of participants, including reasons for any exclusions or missing Week 12 measurements, is not reported in the registry record.

The outcome schedule includes a primary Week 12 change in weekly itch severity and secondary measures covering symptom activity, hives, time to response, skin-related quality of life, and angioedema-free days. The record posts results for the primary outcome and selected secondary outcomes, but not detailed results for every listed outcome. The design gives a structured comparison across doses; interpretation still depends on the reported analysis, its uncertainty, and the incompleteness of some methods and outcome details.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Modified intent-to-treat population: All randomized patients who received at least one dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline in the Weekly Itch Severity Score at Week 12, measured over Baseline, Week 12.

The primary endpoint is the change from baseline in the weekly itch severity score at Week 12. The weekly score sums daily itch severity scores over 7 days. Each daily score is the average of morning and evening ratings on a scale from 0, none, to 3, severe. The weekly score ranges from 0 to 21, and a higher score means more severe itching. The baseline value is based on the 7 days before the first treatment. A negative change indicates improvement from baseline.

This endpoint converts repeated daily symptom ratings into a single summary for a defined week. That can make the outcome easier to compare across treatment groups than a collection of individual daily ratings. It also retains more gradation than a simple responder/not-responder classification: participants can have different amounts of change even if they do not cross a chosen response threshold. This is a general reason to use a continuous score as a primary outcome; the registry does not state why this endpoint was selected for this particular trial.

The reported arm values are mean changes, with standard deviations describing the spread of individual changes around each group mean. A mean change shows the average direction and magnitude within an arm, not the treatment effect by itself. The comparison with placebo is the relevant between-group estimate. In this record, the sponsor reports least-squares mean differences from ANCOVA, while the re-calculated comparisons use unadjusted arm summaries. These answer related but not identical statistical questions.

The measure captures itch severity, not every aspect of chronic urticaria or the patient’s overall health. The registry lists additional outcomes for broader symptom activity, hive measures, quality of life, and angioedema-free days. The primary score therefore gives a focused, prespecified-looking symptom summary, while the secondary outcomes offer complementary perspectives; the record does not report the rationale for the endpoint hierarchy.

7. Results Posted in the Registry

• Omalizumab 75 mg: mean -5.87 versus -5.14 on control; difference -0.73 (95% CI -2.59 to 1.13), standardized effect d = -0.12; z-test p = 0.442.
• Omalizumab 150 mg: mean -8.14 versus -5.14 on control; difference -3.00 (95% CI -4.86 to -1.14), standardized effect d = -0.50; z-test p = 0.002.
• Omalizumab 300 mg: mean -9.77 versus -5.14 on control; difference -4.63 (95% CI -6.43 to -2.83), standardized effect d = -0.80; z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Omalizumab 75 mg: mean -13.08 versus -10.36 on control; difference -2.72 (95% CI -6.47 to 1.03), standardized effect d = -0.22; z-test p = 0.155.
  • Omalizumab 150 mg: mean -17.89 versus -10.36 on control; difference -7.53 (95% CI -11.37 to -3.69), standardized effect d = -0.60; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Omalizumab 75 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Omalizumab 150 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change From Baseline in the Weekly Number of Hives Score at Week 12

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Omalizumab 75 mg: mean -7.21 versus -5.22 on control; difference -1.99 (95% CI -4.08 to 0.10), standardized effect d = -0.29; z-test p = 0.062.
  • Omalizumab 150 mg: mean -9.75 versus -5.22 on control; difference -4.53 (95% CI -6.67 to -2.39), standardized effect d = -0.65; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Omalizumab 75 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Omalizumab 150 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12

• Endpoint type: Time to event: compared as a hazard ratio.
• Test: Hazard ratio as reported by the sponsor (Cox proportional hazards model); it was not recalculated.
• Result:
  • Placebo vs Omalizumab 75 mg: hazard ratio 1.43 (95% CI 1.00–2.05), reported p = 0.048 (as reported in the registry).
  • Placebo vs Omalizumab 150 mg: hazard ratio 1.59 (95% CI 1.12–2.26), reported p = 0.010 (as reported in the registry).
• Interpretation:
  • The 95% confidence interval includes no difference (a ratio of 1), so these data do not show a statistically significant difference between Placebo vs Omalizumab 75 mg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference (a ratio of 1), so the hazard of the event is statistically higher for Placebo vs Omalizumab 150 mg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The posted secondary results generally point in a similar direction to the primary outcome: the arm summaries for the available symptom measures show more negative mean changes in the higher-dose groups than in placebo, while the 75 mg comparisons are less clearly separated. This broad pattern is contextual support for reading the primary result alongside measures of overall urticaria activity and hive burden. It is not a substitute for the primary endpoint or a formal demonstration that the measures all show the same treatment effect.

The registry lists outcomes beyond the detailed secondary results shown in the posted tables, including response timing, threshold-based symptom status, itch response, hive size, dermatology-related quality of life, and angioedema-free days. Detailed numerical results are not included for every listed secondary outcome. Their absence from the posted summaries means that no overall conclusion across every secondary measure can be drawn from the displayed results.

Secondary outcomes can help show whether a primary finding is accompanied by changes in related aspects of the condition. However, multiple outcomes and dose comparisons increase the chance of obtaining apparently notable results by chance. Unless the analysis accounts for that multiplicity, individual secondary p-values provide less secure evidence than a single prespecified primary comparison. The registry does not report whether these secondary tests were adjusted or arranged in a formal testing hierarchy.

Thus, the secondary pattern is useful as supporting context, but should not be counted as a series of independent confirmations. Their measures may also be correlated because they reflect related symptoms, so agreement across them does not necessarily provide wholly separate evidence. Interpretation should prioritize the sponsor-reported primary analysis and treat the secondary results as exploratory or supportive when multiplicity procedures are not reported.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12
• Change From Baseline in the Weekly Number of Hives Score at Week 12
• Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12
• Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12
• Percentage of Weekly Itch Severity Score MID Responders at Week 12
• Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12
• Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12
• Percentage of Angioedema-free Days From Week 4 to Week 12

9. Statistical Interpretation

10. Statistical Methods Explained

These results combine arm-level summaries, sponsor-reported model estimates, and simple re-calculations from the posted summary statistics. They should be kept distinct: each serves a different descriptive or inferential purpose.

What the group means describe

The mean change is the average change in the weekly itch score among participants in an arm. The standard deviation describes how dispersed the participants’ changes are around that mean. A negative arm mean indicates an average decrease from baseline, according to the endpoint definition. Because placebo participants also had a negative mean change, the arm means alone cannot identify how much of the change is attributable to treatment rather than changes that also occurred in the comparator group. Comparing arms is necessary to address the trial question.

What a between-group difference describes

A mean difference compares the average change in one treatment arm with the average change in placebo. Negative estimates mean the omalizumab group’s change was more negative than the placebo group’s change. The sponsor’s measure is a least-squares mean difference from ANCOVA. A least-squares mean is a model-based estimate, generally adjusted for factors included in the model. The registry reports ANCOVA as the method, but the covariates, model specification, and handling of baseline values are not reported in the registry record. The adjusted estimate therefore cannot be independently reconstructed from the information posted.

The re-calculated comparisons are simple, unadjusted calculations from the posted arm means and standard deviations. They are not the sponsor’s ANCOVA. The associated p-values and intervals are approximate unadjusted results, rather than replacements for the sponsor’s analysis. Since the record flags a discrepancy between the recalculation and sponsor analysis, the sponsor’s own analysis takes precedence. A difference between the two can arise because the estimands and methods differ; without model details, the precise source of any difference is not reported in the registry record.

How to read the confidence interval

A confidence interval gives a range of estimates compatible with the data and the stated statistical procedure. It conveys uncertainty as well as direction. An interval that includes zero does not rule out no average difference at the conventional two-sided significance level, while an interval entirely below zero indicates that the estimates within that interval favor a more negative change in the omalizumab group. This is a general interpretation of intervals for a mean difference. A confidence interval is not a guarantee that the true effect lies inside its endpoints, and it does not measure the probability that the treatment effect has a particular value.

The p-value describes how unusual the observed data, or data more extreme, would be under a specified null model. It is not the probability that the null hypothesis is true, and it does not quantify clinical importance. The sponsor reports p-values for its ANCOVA comparisons. The re-calculations also show unadjusted p-values; because these are not the sponsor’s model results, the sponsor-reported values are the appropriate reference for the trial’s main comparisons.

Multiplicity and secondary analyses

Testing several doses against placebo and examining many secondary outcomes creates multiple opportunities to see apparently notable results by chance. An adjustment for multiplicity can change the interpretation of individual p-values and intervals. The registry record does not report whether multiplicity was controlled, what testing hierarchy was used, or whether the secondary comparisons were adjusted. General statistical practice is to give greater weight to a designated primary endpoint and to interpret unadjusted secondary findings more cautiously. The absence of reported multiplicity details means that the strength of family-wise evidence cannot be assessed from this record alone.

Other analysis details that matter

The primary analysis population is defined as randomized patients who received at least one dose. That definition is narrower than all randomized patients if some randomized participants did not receive treatment. The record does not give the analysis population’s detailed inclusion flow, nor does it describe how missing Week 12 scores were handled. Methods such as imputation, model-based use of incomplete records, or other approaches can affect estimates; none should be assumed. The registry also does not report whether the primary analysis was based on a particular assumption about outcomes after treatment discontinuation.

The endpoint is continuous, and the reported arm summaries include standard deviations. General interpretation of a mean and its standard error depends on the sampling distribution and the analysis model. The sponsor used ANCOVA; its assumptions and diagnostics are not described. The record does not report sensitivity analyses, robustness checks, or subgroup analyses for this primary outcome. That does not show that such analyses were or were not conducted; their status is not reported in the registry record.

What the methods can and cannot establish

The reported randomized comparisons support a causal interpretation more strongly than an uncontrolled comparison would, because random allocation is intended to balance relevant factors between groups. Still, the reported result is conditional on the study population, outcome definition, follow-up time, analysis population, and statistical methods. The posted estimates do not by themselves describe longer-term response, all symptoms, or outcomes beyond those recorded. The registry’s summary is sufficient to explain the direction and precision of the primary comparisons, but not to reproduce the adjusted analysis or fully assess every analytic assumption.

11. Confidence Intervals and Precision

The sponsor’s confidence intervals convey the uncertainty around the adjusted comparison with placebo. For the 75 mg group, the 95% interval runs from -2.54 to 1.16 and crosses zero. It is therefore compatible with a range of differences that includes no average separation, as well as differences in either direction. The corresponding p-value is 0.464. This estimate is less precise in the practical sense that its interval does not settle the direction of the comparative effect.

For the 150 mg group, the 95% interval runs from -4.85 to -1.24. For the 300 mg group, it runs from -6.49 to -3.13. Both intervals are below zero, indicating that the adjusted estimates are consistently in the direction of more negative change relative to placebo. The widths show that the exact magnitude remains uncertain. The intervals do not determine whether the estimated changes meet a clinically important threshold, and the registry does not report such a threshold for this primary endpoint.

In general, a confidence interval is more informative than a p-value alone because it presents a range of plausible values under the analysis method, rather than only a measure of incompatibility with a null value. It is important not to interpret a 95% interval as a 95% probability that the true effect lies within this particular interval. Its repeated-sampling interpretation is tied to the method and assumptions used to construct it.

These are sponsor-reported ANCOVA intervals. The registry also displays re-calculated unadjusted intervals based on arm-level summaries, but they are not substitutes for the sponsor’s adjusted analysis. The registry flags a discrepancy, so the sponsor’s analysis takes precedence. The precision of any estimate also depends on the analysis population and missing-data approach; those details are not fully reported. Consequently, the intervals characterize uncertainty under the posted analysis, not every uncertainty about how the trial was conducted or analyzed.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size section is a planning illustration based on the observed effects, not a report of the trial’s original design calculation. For the continuous-outcome comparisons, the figures are participants per arm. For the time-to-event comparisons, the figures are total events across the comparison. The table identifies rows as planning for the observed effect or for a smaller fraction of that observed effect, and presents separate columns for 80% and 90% power.

In plain language, the 80% power column estimates how many participants per arm, or total events for a time-to-event comparison, a hypothetical study would need to have an 80% chance of detecting the stated effect under the listed assumptions. The 90% column uses a higher chance of detecting that effect, and therefore gives a larger planning requirement. These are planning quantities, not counts observed in this trial.

The stated assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is the stated fraction of the observed effect. The time-to-event calculations use the Schoenfeld method and report total events. The original design assumptions and sample-size justification are not reported in the registry record.

Smaller effects are harder to distinguish from random variation, so the planning table shows larger requirements as the assumed effect becomes a smaller fraction of the observed effect. This is a general relationship in study planning. It does not mean that a future study will produce the same effect as this one. The figures are not observed power, and they should not be read as evidence that the completed trial was adequately or inadequately powered for its original purpose.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = -0.730; pooled standard deviation σ = 6.039.
2. n = 2 × (1.96 + 0.842)² × 6.039² / -0.730² = 1,074.3, rounded up to 1,075 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- -0.73                      # observed difference in means
sigma <- 6.03888953305596                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(1292473)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 1,075 (80% power), 1,439 (90% power)
 75% of observed effect: n per arm = 1,910 (80% power), 2,557 (90% power)
 50% of observed effect: n per arm = 4,298 (80% power), 5,753 (90% power)
power.t.test: 1075.2 
Simulated power at n = 1,075 per arm: 0.804 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The sponsor’s primary comparisons use ANCOVA and are reported as least-squares mean differences with 95% confidence intervals and p-values. The re-calculated comparisons use unadjusted differences from the posted arm-level means and standard deviations. They are simpler summary-statistic calculations, not an attempt to recreate the sponsor’s adjusted model.

For the primary endpoint, the sponsor’s reported estimates are -0.69 for 75 mg, -3.04 for 150 mg, and -4.81 for 300 mg. The re-calculated estimates are close in direction, but do not match exactly. The 75 mg comparison is compatible with no difference in both presentations; the reported 150 mg and 300 mg sponsor intervals lie below zero. The record flags a discrepancy between the recalculation and sponsor analysis. Accordingly, the sponsor’s own analysis takes precedence for interpreting the trial’s primary comparisons.

This difference does not, by itself, show that either calculation is erroneous. Adjusted and unadjusted estimates can differ because they use different statistical procedures and may target estimates with different adjustment. However, the covariates and full model details are not reported in the registry record, so the sponsor’s exact adjustment cannot be reproduced or fully examined from the posted information. The unadjusted results are best treated as a transparent descriptive check, while the sponsor’s ANCOVA results are the reported trial analysis.

15. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome and multiple secondary outcomes, and the primary endpoint is compared across several dose groups. This creates a multiplicity question: when many outcomes or treatment comparisons are examined, the probability of at least one apparently notable result can increase even if there is no underlying difference. Statistical procedures can address this through adjusted significance thresholds, a prespecified testing hierarchy, or other approaches.

Whether any such procedure was used for this trial is not reported in the registry record. The record does not describe a hierarchy among the doses, the order of testing, or an adjustment for the secondary endpoints. The sponsor-reported primary p-values can be described as posted, but the record does not permit a full assessment of how multiplicity was handled. The secondary p-values should consequently be read cautiously rather than as definitive evidence across the whole set of outcomes.

The primary endpoint population is stated as randomized participants who received at least one dose of study drug. The record does not report the specific analysis population counts by outcome in a way that explains every difference in available arm summaries. Nor does it report the handling of missing Week 12 measurements, withdrawal, or treatment discontinuation. Missing data can affect an estimate if the participants with recorded outcomes differ systematically from those without them. Without the method and assumptions, the reader cannot determine how this issue was addressed.

The record reports ANCOVA for the primary analysis but does not state the included covariates, detailed model specification, or diagnostic checks. It also does not report sensitivity analyses examining alternative missing-data assumptions. These omissions limit independent reproduction and robustness assessment. They do not establish that the analyses or procedures were absent; they establish that the relevant details are not reported in the registry record.

The original sample-size rationale, interim analysis plans, and analysis-plan details are also not reported. Those items matter for understanding what the study was designed to detect and how the final analyses were selected. The planning illustrations elsewhere on the page are based on observed effects and stated planning assumptions; they cannot fill in the trial’s original design rationale.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: angioedema (1.3%), haemorrhoids (1.3%), melaena (1.3%), pneumonia (1.3%), tonsillectomy (1.3%).

The posted serious adverse event counts are presented separately for each group. The registry lists 2 serious adverse events among 79 participants at risk in the placebo group, 1 among 76 at risk in the 75 mg group, 1 among 88 at risk in the 150 mg group, and 5 among 79 at risk in the 300 mg group. These are descriptive counts during the reported study record. They do not, on their own, establish that a treatment caused an event or allow a reliable comparative safety conclusion.

The group sizes at risk for these safety summaries differ from the arm counts shown for the primary endpoint. Safety and efficacy summaries can use different populations or definitions, but the specific reasons for these differences are not reported in the registry record. The registry also lists six serious adverse event terms, each with a reported frequency of 1.3%: angioedema, haemorrhoids, melaena, pneumonia, tonsillectomy, and malignant melanoma in situ. The posted summary does not establish that these terms occurred in each treatment group.

Death counts are not reported in the registry record. The figures are not a complete account of all safety outcomes, and counts alone do not convey event timing, duration, severity beyond the serious classification, or the participants’ clinical context. They should be read as registry-reported descriptive information, not as a standalone comparison of risks.

17. What the Result Does, and Does Not, Mean

The primary result describes average change in a symptom score at Week 12 among the trial’s modified intent-to-treat population. The sponsor-reported comparisons for the 150 mg and 300 mg groups are below zero, with confidence intervals that do not cross zero. The 75 mg interval includes zero. This tells the reader how the posted adjusted estimates compare with placebo and how uncertain those estimates are under the reported model.

It does not mean that every participant experienced the average change, or that an individual’s symptom response can be predicted from the group mean. The standard deviations show that individual changes varied around the group averages. Nor does an average difference establish how many participants experienced a meaningful improvement. The registry reports separate responder outcomes, but the results do not supply a clinical importance threshold for the primary mean difference.

The result applies to the population and time point studied: adolescent and adult participants aged 12-75 with chronic idiopathic or spontaneous urticaria who remained symptomatic despite H1 antihistamine treatment, assessed at Week 12. The posted primary endpoint does not establish the duration of any response beyond that period, the outcome in populations not represented in this study, or effects on every aspect of the condition.

Statistical evidence and clinical importance are related but distinct. A confidence interval and p-value describe compatibility with a statistical model and a null comparison; they do not determine whether a difference matters to patients. The record does not report a minimum clinically important difference for the primary endpoint, and it does not provide enough information to derive one.

Finally, the registry summary is not a full clinical study report. The original sample-size rationale, detailed missing-data methods, full ANCOVA specification, and multiplicity procedures are not reported. These limits do not erase the posted comparisons, but they constrain how completely the analysis can be audited or generalized. This page describes the registry results and their statistical precision; it does not make a treatment recommendation.

18. Why This Trial Matters Statistically

This trial is statistically instructive because it reports a randomized, double-blind, placebo-controlled comparison with three dose groups and a continuous primary symptom measure. It allows readers to distinguish within-arm change from the comparative question: whether change in an omalizumab group differed from change in placebo. That distinction matters whenever participants in the comparator group also show change over time.

The record also illustrates why adjusted estimates and simple recalculations should not be conflated. The sponsor used ANCOVA and reported least-squares mean differences, whereas the transparent re-calculations use unadjusted arm summaries. Their results are related, but they are not identical analyses. The discrepancy flag makes it especially important to identify the sponsor’s model results as the main reported analysis rather than presenting the recalculation as a replacement.

Confidence intervals add information that a p-value alone cannot supply: they show a range of estimates compatible with the analysis and make the contrast between an interval spanning zero and intervals lying below zero visible. At the same time, they do not settle clinical importance. The record does not give a clinical threshold for the primary score, so statistical separation should not be translated automatically into a claim about the size of benefit that matters to patients.

Finally, the many secondary measures make multiplicity and incomplete reporting relevant. A coherent pattern across related measures can be informative, but unadjusted results should not be treated as independent confirmations. By separating primary evidence, secondary context, precision, safety counts, and unreported methods, readers can see both what the registry establishes and what it leaves unresolved.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not provide the full statistical analysis plan or enough detail to reproduce the sponsor’s ANCOVA. Its covariates, model specification, diagnostic checks, and sensitivity analyses are not reported. The record flags a discrepancy with simple unadjusted re-calculations, so the sponsor’s analysis takes precedence, but the reason for the exact differences cannot be verified from the information posted.

Missing-data handling is not reported. The record defines the primary analysis population as randomized patients who received at least one dose, but it does not explain the disposition of all randomized participants, reasons for missing Week 12 values, or assumptions used for incomplete outcomes. The original sample-size justification and interim analysis plans are also not reported. The observed-effect planning illustrations should not be mistaken for those original design details.

Multiplicity procedures are not reported despite several dose comparisons and multiple listed secondary outcomes. This limits the certainty that can be assigned to secondary findings. Detailed posted results are also not available for every listed secondary endpoint, so the overall consistency of all intended measures cannot be evaluated from these summaries.

The endpoint is a patient symptom score over a specified week and does not alone describe every manifestation of urticaria or the durability of response. The posted primary result is at Week 12; longer-term primary endpoint results are not reported in the record. The record also does not report a clinical importance threshold for the primary mean difference.

Safety summaries are counts and listed event terms. They do not provide the full context needed to assess event timing, exposure, or causal attribution, and death counts are not reported in the registry record. These limitations are specific to the posted record and should be distinguished from evidence that any particular method or analysis was not conducted.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) — NCT01292473.
• Registry record last updated 2013-10-11; status last verified 2013-10.
• Results first posted 2013-09-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

This completed Phase III study compared placebo with subcutaneous omalizumab at 75 mg, 150 mg, and 300 mg every 4 weeks in patients with chronic idiopathic or spontaneous urticaria who remained symptomatic despite H1 antihistamine treatment. The primary endpoint was change from baseline in weekly itch severity at Week 12, analyzed in a modified intent-to-treat population.

The sponsor reported ANCOVA comparisons with placebo. The 75 mg confidence interval included zero; the 150 mg and 300 mg intervals were below zero. Simple unadjusted recalculations are also shown, but the sponsor’s analysis takes precedence because the registry flags a discrepancy. Secondary outcomes offer related symptom context, while multiplicity methods, missing-data handling, and several other analysis details are not reported in the registry record.

Safety information is presented descriptively as serious adverse event counts and selected terms. The sample-size illustrations are planning exercises based on observed effects, not the trial’s original design calculations. Overall, the registry supports interpretation of the posted Week 12 comparisons, while leaving important details of analysis methods and broader outcome interpretation unresolved.